- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07620808
MTM2MTG Pilot Ancillary Study (MTM2MTG)
18 augustus 2026 bijgewerkt door: Nour Makarem, PhD, Columbia University
Medically Tailored Groceries for Cardiovascular Health
The investigators will conduct an ancillary study of participants in a completed RCT of medically tailored meals to determine whether transitioning these participants to a medically tailored groceries (MTG) program is a feasible approach to sustain health effects.
Studie Overzicht
Toestand
Aanmelden op uitnodiging
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This ancillary study is a single arm, pre-post design among adults with co-existing type 2 diabetes and elevated to high blood pressure who do not currently qualify for medically tailored meals (MTMs) but received them as part of their participation in an 8-month RCT on MTMs and cardiometabolic outcomes.
The purpose of the ancillary study is to determine whether transitioning participants from a MTM to a MTG program (i.e., a hybrid MTM to MTG intervention) is a feasible approach to improve outcomes and sustain health effects.
Participants will receive one box of medically tailored groceries each week for a period of 4 months, with each box supporting preparation of approximately 10 meals per week.
No additional baseline visit will be required, as measurements collected at the 8-month visit in the parent clinical trial will serve as baseline values for the ancillary study.
All participants will have their HbA1c and blood pressure measured and complete questionnaires about their diet quality, health and lifestyle behaviors, and program engagement and implementation at 4 months post receiving their first MTG box.
Studietype
Ingrijpend
Inschrijving (Geschat)
80
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10032
- Columbia University Mailman School of Public Health
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Type 2 diabetes diagnosis (physician diagnosed or HbA1c greater than or equal to 6.5% or diabetes medication use)
- Hypertension diagnosis (systolic blood pressure greater than or equal to 130 mmHg and/or diastolic blood pressure greater than or equal to 80 mmHg or physician diagnosis or hypertension medication use) or elevated blood pressure (defined as systolic blood pressure greater than or equal to 120 mmHg)
- Participation in parent trial investigating the impact of an 8-month medically-tailored meals (MTMs) intervention on cardiometabolic outcomes among adults with type 2 diabetes and elevated to high blood pressure who do not currently qualify for MTMs.
Exclusion Criteria:
- Cancer diagnosis
- Undergoing cancer treatment
- Non-English or non-Spanish speaking
- Not cognitively able to complete study requirements
- Severe psychiatric disorders
- Inability to provide informed consent
- Health conditions that could prevent safe participation or impact study outcomes (e.g., substance use disorder, dialysis, neurodegenerative conditions)
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Ancillary Study: Medically Tailored Groceries (MTG) Program
Participants in this ancillary study are adults with type 2 diabetes and elevated to high blood pressure who do not currently qualify for medically tailored meals (MTMs) but received them as part of a RCT for 8 months.
This ancillary study evaluates whether transitioning from MTMs to MTGs is a feasible approach to maintain MTM intervention health effects and could be a better tolerated intervention for participants who are not engaged with the MTM intervention.
Participants will receive one MTG box per week for 4 months, supporting preparation of ~10 heart healthy, diabetes appropriate meals per week.
Outcomes will be assessed at the end of the 4-month MTG intervention period using questionnaires and clinic measurements (blood pressure and HbA1c).
The 8-month primary endpoint visit for the parent RCT will serve as the baseline for this study.
|
God's Love We Deliver's current MTG program (Health Harvest), which consists of weekly home-delivered MTG boxes, recipes and educational materials/webinars developed by Registered Dietitian Nutritionist for a 4-month period.
The participants in the ancillary study will receive 1 MTG box/week which provides food sufficient for approximately 10 meals/week and includes fresh fruits, vegetables, whole grains, and proteins for a period of 4 months.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Diet Quality
Tijdsspanne: Baseline, 4 months
|
The Mediterranean Eating Pattern for Americans (MEPA) scale, which captures adherence to a heart healthy dietary pattern, will be used to assess diet quality.
The MEPA score ranges from 0-16 with higher scores indicating better diet quality.
The change in MEPA scores from baseline to 4 months will be calculated.
|
Baseline, 4 months
|
|
Change in HbA1c
Tijdsspanne: Baseline, 4 months
|
A fast and accurate HbA1c fingerstick test will assess changes in glycemic control from baseline to 4 months.
|
Baseline, 4 months
|
|
Change in systolic blood pressure
Tijdsspanne: Baseline, 4 months
|
The change in office systolic blood pressure (mmHg) from baseline to 4 months will be calculated.
|
Baseline, 4 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in diastolic blood pressure
Tijdsspanne: Baseline, 4 months
|
The change in office diastolic blood pressure (mmHg) from baseline to 4 months will be calculated.
|
Baseline, 4 months
|
|
Acceptability of Implementation
Tijdsspanne: 4 monthd
|
Acceptability will be measured by questionnaire.
Items are adapted from the validated Acceptability of Implementation Measure (AIM) and are rated on a 5-point Likert scale ranging from 1 to 5, with 1 indicating "Completely disagree" and 5 indicating "Completely agree."
Higher scores indicate better intervention acceptability.
The items are analyzed individually and not summed to a total score.
|
4 monthd
|
|
Feasibility of Implementation
Tijdsspanne: 4 months
|
Feasibility will be measured by questionnaire using items adapted from the validated Feasibility of Implementation Measure (FIM) and rated on a 5-point Likert scale ranging from 1 to 5, with 1 indicating "Completely disagree" and 5 indicating "Completely agree."
Higher scores indicate better feasibility.
The items are analyzed individually and not summed to a total score.
|
4 months
|
|
Appropriateness of Implementation
Tijdsspanne: 4 months
|
Appropriateness will be measured by questionnaire.
Items are adapted from the validated Implementation Appropriateness Measure (IAM) and are rated on a 5-point Likert scale ranging from 1 to 5, with 1 indicating "Completely disagree" and 5 indicating "Completely agree."
Higher scores indicate better appropriateness.
The items are analyzed individually and not summed to a total score.
|
4 months
|
|
Satisfaction with Intervention
Tijdsspanne: 4 months
|
Satisfaction with the intervention components will be measured by questionnaire.
Participants will rate their satisfaction with intervention by indicating how likely they are to recommend it to others on a 10-point scale with higher scores indicating greater satisfaction (net promoter score).
They will also be asked to rate the quality of the intervention as poor, fair, good, very good, or excellent.
The items are analyzed individually and not summed to a total score.
|
4 months
|
|
Food Insecurity
Tijdsspanne: Baseline, 4 months
|
The USDA Household Food Security Survey (FSSM-6 item) will be administered at baseline, 3 months, and 8 months.
The scores range from 0-6 such that a score of 0-1 indicates high or marginal food security, 2-4 indicates low food security, and 5-6 indicates very low food security.
Changes in the score from baseline to follow up at 4 months.
|
Baseline, 4 months
|
|
Nutrition Insecurity
Tijdsspanne: Baseline, 4 months
|
The Gretchen Swanson 4-item nutrition screener will be administered at baseline, 4 months (score range: 0-4 with higher scores indicating higher nutrition security).
Changes in the score from baseline to follow up at 4 months will be evaluated.
|
Baseline, 4 months
|
|
Sleep Duration
Tijdsspanne: Baseline, 4 months
|
Sleep duration will be self-reported using the Pittsburgh Sleep Quality Index (PSQI, score range: 0-21).
Changes in self-reported habitual hours of sleep from baseline to follow up at 4 months will be evaluated.
|
Baseline, 4 months
|
|
Pittsburgh Sleep Quality Index
Tijdsspanne: Baseline, 4 months
|
Global sleep quality will be measured using the Pittsburgh Sleep Quality Index (PSQI, score range: 0-21).
Changes in the overall PSQI score (continuous and categorical) and its components from baseline to follow up at 4 months will be evaluated.
|
Baseline, 4 months
|
|
Self-rated health
Tijdsspanne: Baseline, 4 months
|
Participant will rate their health as excellent, very good, good, fair, or poor at baseline,4 months.
Changes in self-rated health from baseline to follow up at 4 months will be computed.
|
Baseline, 4 months
|
|
General Health Status
Tijdsspanne: Baseline, 4 months
|
The EuroQoL 5-Dimension 5-Level (EQ-5D-5L) will be used to measure general health status and quality of life.
This will be captured based on five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, and each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Based on the participant's response for reach dimension they will receive a 1-digit number, and the digits for the five dimensions will be combined into a 5-digit number that describes the patient's health state.
This study will evaluate changes in this measure from baseline to follow up at 4 months.
I
|
Baseline, 4 months
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Hoofdonderzoeker: Nour Makarem, PhD, FAHA, Columbia University
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 augustus 2026
Primaire voltooiing (Geschat)
1 juni 2027
Studie voltooiing (Geschat)
1 juni 2027
Studieregistratiedata
Eerst ingediend
27 mei 2026
Eerst ingediend dat voldeed aan de QC-criteria
27 mei 2026
Eerst geplaatst (Werkelijk)
2 juni 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
19 augustus 2026
Laatste update ingediend die voldeed aan QC-criteria
18 augustus 2026
Laatst geverifieerd
1 augustus 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- AAAV0681 - Ancillary Study
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Beschrijving IPD-plan
Data may be shared upon request to PI.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .